搜尋結果
2022年3月30日 · The efficacy of ivermectin in preventing hospitalization or extended observation in an emergency setting among outpatients with acutely symptomatic coronavirus disease 2019 (Covid-19), the...
- Recommendation
- Rationale
- References
The Panel recommends against the use of ivermectin for the treatment of COVID-19 (AIIa).
The Panel’s recommendation is primarily informed by adequately powered, randomized trials of ivermectin that reported clinical outcomes. Studies that randomized participants to receive ivermectin or a matched placebo had the greatest impact on the Panel’s recommendation.6-13
Trials have failed to find a clinical benefit of using ivermectin to treat COVID-19 in outpatients. In TOGETHER, an adaptive platform trial conducted in Brazil, there was no apparent difference between the ivermectin and placebo arms for the primary outcome of risk of emergency department visits or hospitalization (14.7% vs. 16.4%).14 In addition, there was no statistically significant difference between the ivermectin and placebo arms in mortality (3.1% vs. 3.5%). In COVID-OUT, a randomized factorial trial, the use of ivermectin did not reduce the occurrence of a composite outcome of emergency department visits, hospitalization, or death when compared with a matched control (5.7% vs. 4.1%).6
Omura S, Crump A. Ivermectin: panacea for resource-poor communities? Trends Parasitol. 2014;30(9):445-455. Available at: https://www.ncbi.nlm.nih.gov/pubmed/25130507.
Kircik LH, Del Rosso JQ, Layton AM, Schauber J. Over 25 years of clinical experience with ivermectin: an overview of safety for an increasing number of indications. J Drugs Dermatol. 2016;15(3):325-332. Available at: https://www.ncbi.nlm.nih.gov/pubmed/26954318.
Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020;178:104787. Available at: https://www.ncbi.nlm.nih.gov/pubmed/32251768.
Chaccour C, Hammann F, Ramón-García S, Rabinovich NR. Ivermectin and COVID-19: keeping rigor in times of urgency. Am J Trop Med Hyg. 2020;102(6):1156-1157. Available at: https://www.ncbi.nlm.nih.gov/pubmed/32314704.
2021年8月17日 · 伊維菌素 (Ivermectin) 對 COVID-19 感染症是否有效？. 關鍵資訊. 我們沒有發現任何證據表示使用伊維菌素能有效治療或預防 COVID-19 感染症。. 此佐證資料仍持續更新中，但證據仍然有限。. 目前仍有 31 項針對伊維菌素的研究在進行中，我們將在其得出結論後更新本 ...
2022年12月14日 · Given the wide availability and low cost of ivermectin and that the dosage used in the trial appeared to be safe, such treatment effects could be an important benefit for high-risk patients who...
2021年6月21日 · Low-certainty evidence found that ivermectin prophylaxis reduced COVID-19 infection by an average 86% (95% confidence interval 79%–91%). Secondary outcomes provided less certain evidence.
- Andrew Bryant, Theresa A Lawrie, Therese Dowswell, Edmund J Fordham, Scott Mitchell, Sarah R Hill, T...
- 10.1097/MJT.0000000000001402
- 2021
- Am J Ther. 2021 Jul-Aug; 28(4): e434-e460.
2021年12月21日 · A schematic of the key cellular and biomolecular interactions between ivermectin, host cell, and SARS-CoV-2 in COVID-19 pathogenesis and prevention of complications has been proposed.
2021年3月31日 · 针对国际上对伊维菌素作为COVID-19潜在治疗手段的日益关注，成立了一个指南制定小组。 这是一个由国际专家组成的独立专家小组，包括多专业领域的临床护理专家，还包括一个伦理学家和一些患者合作伙伴。 该小组回顾了来自16项随机对照试验（共纳入2407例患者）的汇总数据，包括住院和门诊的COVID-19患者。 他们认为，由于可用的试验数据规模小以及存在方法学限制（包括事件数量少），关于伊维菌素能否降低COVID-19患者的死亡率、机械通气需求、住院需求和临床改善时间的证据“确定性非常低”。 专家小组没有对使用伊维菌素预防COVID-19的情况进行研究，那不属于现行指南的范围。 对编辑的说明： 之前发布的对COVID-19疗法使用的建议：
